S
Starget Pharma
Biotech & Life Sciences · Ramat Hasharon, Israel · Founded 2019
This company is developing new targeted radiopharmaceutical technologies to treat solid tumors MoreLess
Starget Pharma specializes in the development of targeted molecular radiotherapy for advanced metastatic cancers. This innovative approach combines radioactive imaging tracers with targeted radiotherapy to diagnose and treat cancer with high precision. The company focuses on creating radioligands, which are composed of a radionuclide for imaging or treatment and a molecular ligand for targeted delivery. These radioligands enable the precise delivery of radiation to cancer cells while minimizing damage to healthy tissues. Starget Pharma's core technology leverages peptide backbone dynamics to enhance the drugability of these radioligands, making them highly effective in treating cancers such as prostate and neuroendocrine tumors. The company operates in the nuclear oncology market, serving healthcare providers and patients with limited or non-existent treatment options. Starget Pharma generates revenue through the development and commercialization of its proprietary radiopharmaceutical products.
Keywords: radiopharmaceuticals, targeted therapy, cancer treatment, radioligands, nuclear oncology, peptide engineering, precision medicine, metastatic cancer, prostate cancer, neuroendocrine tumors.
Company overview
Starget Pharma company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2019
- Headquarters
- Ramat Hasharon, Israel
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 76.2
Valuation & funding
Starget Pharma funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2026 | $18M | $72M | STAR TREE VENTURES · Cancer Focus Fund · astr partners · Ilex Medical | ↗ |
| EARLY VC✓Equity / VC | Oct 2024 | $5.1M | $50M | Cancer Focus Fund | ↗ |
| EARLY VC✓Equity / VC | Dec 2021 | $10M | $40M | Ilex Medical | ↗ |
| SPINOUT✓Other financing | Jan 2019 | $0 | — | Tel Aviv University | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 20 |
| 2025 | 18 |
| 2024 | 16 |
| 2023 | 9 |
| 2022 | 5 |
| 2021 | 5 |
Growth signals
Starget Pharma website traffic
Latest recorded traffic for Starget Pharma is 1.2K monthly website visits, up 2900% over the last three months. Starget Pharma's team grew 16.7% over the past year.
Comparisons
Starget Pharma compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Starget Pharma's talent
Source: Dealroom Talent Intelligence.
Investors
7 investors on Starget Pharma's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Starget Pharma has talent and traffic
team presence
In the news
Latest news about Starget Pharma
Recent press, funding announcements, and product moves mentioning Starget Pharma — open to read from the original sources.
Market sentiment
What the market is saying about Starget Pharma
An AI-synthesized read of the highest-engagement posts about Starget Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Starget Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.